Press Releases

Jazz Pharmaceuticals Investor & Media Relations
Investors: investorinfo@jazzpharma.com
Media: mediainfo@jazzpharma.com
Ireland, +353 1 634 7892
U.S., +1 650 496 2800
Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle  
10/21/14Jazz Pharmaceuticals to Report 2014 Third Quarter Financial Results on November 4, 2014
DUBLIN, Oct. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 third quarter financial results on Tuesday, November 4, 2014, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to provide a business and financial update and discuss third quarter 2014 financial results. Interested parties may access the live audio webcast via... 
 Printer Friendly Version
08/08/14Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes
DUBLIN, Aug. 8, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior notes due 2021.  The Issuer has also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes from the Issuer solely to cover over-allotment... 
 Printer Friendly Version
08/06/14Jazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes
DUBLIN, Aug. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of exchangeable senior notes due 2021 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  In connection with the offering, the I... 
 Printer Friendly Version
08/05/14Jazz Pharmaceuticals Announces Second Quarter 2014 Financial Results And Updated Guidance
Company Reports Second Quarter 2014 Total Revenues of $291 Million, Driven by Strong Sales of Xyrem, Erwinaze and Defitelio Adjusted EPS of $2.05 and GAAP EPS of $0.70 DUBLIN, Aug. 5, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2014 and updated financial guidance for 2014. "Strong underlying demand for our products and the start of our European Union launch of Defitelio led to significant revenue gr... 
 Printer Friendly Version
08/05/14Jazz Pharmaceuticals Completes Acquisition Of Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.
Jazz Pharmaceuticals owns worldwide rights to defibrotide DUBLIN, Aug. 5, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of its acquisition of rights to defibrotide in the United States (U.S.) and all other countries in the Americas from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau).  Jazz Pharmaceuticals now owns worldwide rights to defibrotide. Defibrotide is a novel product that is marketed by Jazz Pharmaceuticals in the European Union (EU) under ... 
 Printer Friendly Version
08/04/14Jazz Pharmaceuticals Announces Participation at Canaccord Genuity Conference on August 13
DUBLIN, Aug. 4, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Canaccord Genuity 34th Annual Growth Conference in Boston, MA on Wednesday, August 13, 2014 at 9:00 a.m. EDT / 2:00 p.m. IST.  Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update. A live audio webcast of the presentation may be accessed from the Investors se... 
 Printer Friendly Version
07/22/14Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014
DUBLIN, July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss second quarter 2014 financial results. Interested parties may access the live audio webcast via... 
 Printer Friendly Version
07/21/14Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386
DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)--Jazz Pharmaceuticals plc (JAZZ) and Concert Pharmaceuticals, Inc. (CNCE) today announced the initiation of the first Phase 1 clinical trial of JZP-386, a deuterium-containing analog of sodium oxybate—the active ingredient in Xyrem® (sodium oxybate) oral solution. The Phase 1 clinical trial is designed to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JZP-386, and includes Xyrem as an active control. The study is expe... 
 Printer Friendly Version
07/02/14Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.
Jazz Pharmaceuticals to own worldwide rights to defibrotide at closing Investor conference call to be held today, July 2 at 8:30 AM EDT/1:30 PM IST DUBLIN, July 2, 2014  /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) under which a subsidiary of Jazz Pharmaceuticals plc (Jazz) will acquire from Sigma-Tau rights to defibrotide in the United States (U.S.) and all other ... 
Download PDFPrinter Friendly Version
06/02/14Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy
Study Demonstrated Robust Alerting Effect Consistent with Phase 2a Results Planning Phase 3 Clinical Development Program DUBLIN, June 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy.  In the study, all primary and secondary endpoints were met and patients treated with JZP-110... 
 Printer Friendly Version
05/27/14Jazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting
Phase 2b Data for JZP-110 in Adults with EDS in Narcolepsy Accepted as Late-Breaker Oral Presentation Conference Call to be Held Monday, June 2 at 4:00 p.m. CDT / 10:00 p.m. IST DUBLIN, May 27, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that new data for the investigational compound JZP-110 (previously ADX-N05) will be presented at the 28th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, May 31 to June 4, 2014 in Minneapoli... 
 Printer Friendly Version
05/19/14Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
DUBLIN, May 19, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO).  Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company.  He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and dev... 
 Printer Friendly Version
05/13/14Jazz Pharmaceuticals Announces Participation in Two Investor Conferences
DUBLIN, May 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.   UBS Global Healthcare Conference in New York, NY on Tuesday, May 20, 2014 at 8:00 a.m. EDT / 1:00 p.m. IST.  Matt Young, senior vice president and chief financial officer, will provide an overview of the company and a business and financial update.  Goldman Sachs 35th Annual Global Healthcare Co... 
 Printer Friendly Version
05/08/14Jazz Pharmaceuticals Announces First Quarter 2014 Financial Results
Company Reports First Quarter 2014 Total Revenues of $247 Million Driven by Strong Sales of Xyrem, Erwinaze and Defibrotide Adjusted EPS of $1.61 and GAAP EPS of $(1.58) DUBLIN, May 8, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2014 and reaffirmed and updated financial guidance for 2014. "We are pleased with the progress made during the first quarter, highlighted by the completion of two transactio... 
 Printer Friendly Version
04/24/14Jazz Pharmaceuticals to Report 2014 First Quarter Financial Results on May 8, 2014
DUBLIN, April 24, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 first quarter financial results on Thursday, May 8, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss first quarter 2014 financial results. Interested parties may access the live audio webcast via the... 
 Printer Friendly Version
03/31/14Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease
Defitelio®▼ (defibrotide) Launch Announced During the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 DUBLIN and VILLA GUARDIA, Italy, March 31, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®▼ (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease (severe V... 
Download PDFPrinter Friendly Version
02/26/14Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
DUBLIN, Feb. 26, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.  Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Wednesday, March 5, 2014 at 8:00 a.m. EST / 1:00 p.m. GMT.  Matt Young, senior vice president, corporate development, will provide an overview of the company and a business and financial update.  The company recently announced t... 
 Printer Friendly Version
02/25/14Jazz Pharmaceuticals Announces Management Change
Chief Financial Officer Kathryn Falberg to Step Down; Matthew Young Appointed CFO DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Kathryn Falberg, executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests.  Ms. Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period. Matthew Young, senior vice president of corporate development... 
 Printer Friendly Version
02/25/14Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2013 Financial Results
Company Reports Total Revenues of $872 Million in 2013 Driven by Strong Sales of Xyrem and Erwinaze Adjusted EPS of $6.31 and GAAP EPS of $3.51 in 2013 DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter ended December 31, 2013 and provided financial guidance for 2014. "2013 was an outstanding year as we delivered strong top-line growth, generated significant cash flow and executed on ou... 
 Printer Friendly Version
02/21/14Jazz Pharmaceuticals plc Completes Tender Offer For Gentium S.p.A. Shares
Approximately 98 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered DUBLIN, Feb. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the subsequent offering period of the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of Gentium S.p.A. (Nasdaq: GENT) for $57.00 per share and per ADS (without duplication for ordinary sh... 
 Printer Friendly Version
02/11/14Jazz Pharmaceuticals to Report 2013 Fourth Quarter and Full Year Financial Results on February 25, 2014
DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2013 fourth quarter and full year financial results on Tuesday, February 25, 2014, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to provide a business and financial update and discuss fourth quarter and full year 2013 financial results and provide guidance for 2014... 
 Printer Friendly Version
02/11/14Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz™ (clozapine, USP) Oral Suspension
First liquid formulation clozapine for treatment-resistant schizophrenia DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz™ (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.   "We are pleased to offer patients with treatmen... 
 Printer Friendly Version
02/10/14Jazz Pharmaceuticals Breaks Ground On New Manufacturing And Development Facility In Ireland
DUBLIN, Feb. 10, 2014 /PRNewswire/ --Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced that it has commenced construction of a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon, approximately 75 miles east of the company's Dublin headquarters. This is the first manufacturing facility to be built by Jazz Pharmaceuticals.   "Today marks a milestone for Jazz Pharmaceuticals as we break ground in Ireland and begin, for the first time, construc... 
 Printer Friendly Version
01/23/14Jazz Pharmaceuticals plc Announces Minimum Tender Condition Exceeded During Initial Offering Period For Gentium S.p.A. Shares
Approximately 79 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered Subsequent offering period commenced to permit additional shares to be tendered DUBLIN, Jan. 23, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the initial offering period in the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of Gentium S.p.A. (Nasdaq: GENT) f... 
 Printer Friendly Version
01/13/14Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness
Terms include $125 million upfront payment in cash plus a potential of up to $272 million in milestone payments Investor conference call to be held today, January 13 at 8:30 AM EST/1:30 PM GMT DUBLIN, Jan. 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Aerial BioPharma, LLC (Aerial) today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development ... 
Download PDFPrinter Friendly Version
01/06/14Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
DUBLIN, Jan. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company and provide a business and financial update at the conference on Monday, January 13, 2014 at 10:00 a.m. PST / 6:00 p.m. GMT. A live audio webcast of the presentation ma... 
 Printer Friendly Version